The Cancer Letter

Inside information on cancer research and drug development

In Brief

Eric Smith, Andrew Aguirre, Sam Klempner granted additional $300,000 from DeGregorio Family Foundation to study immunotherapy in gastroesophageal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Eric Smith

Andrew Aguirre

Sam Klempner

The DeGregorio Family Foundation, with support from the Torrey Coast Foundation Gastro Esophageal Investigator Network Initiative, or GEMINI, awarded $300,000 to Eric Smith and Andrew Aguirre, both of Dana-Farber Cancer Institute, and Sam Klempner, of Massachusetts General Hospital, to reward the progress they have made on their grant in a little over a year. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

MD Anderson, AmMax Bio announce agreements to develop immunotherapy for MRD-positive cancers

The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account